Clinical trials: Kidney Transplant Immunosuppression
Kidney Transplantation
The Effect of Sirolimus on the Pharmacokinetics of Tacrolimus
The purpose of this study is to understand whether the pharmacokinetics of tacrolimus is influenced by the concurrent use of sirolimus.
- Trial name
- NCT00166829
- Testing
- sirolimus, tacrolimus, mycophenolate mofetil
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
Kidney Transplant Failure and Rejection
BIOtechnology Applied to Renal TRansplantation With IMmunobiogram
Immunobiogram (IMBG) is a novel in vitro diagnostic bioassay developed by Biohope Scientific Solutions for Human Health SL, that allows to measure the pharmacodynamic response to individual immunosuppressive drugs in patients…
- Trial name
- BIOTRAIM (NCT05816486)
- Testing
- Immunobiogram
- Where
- 15 sites in Brazil, France and 3 more
- Volunteers
- 443 people
- Sponsor
- Biohope Scientific Solutions for Human Health, S.L.
Transplanted Organ Rejection
A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney Transplantation
A randomized controlled study to evaluate the safety, efficacy, and overall benefit of FCR001 cell therapy in de novo living donor renal transplantation.
- Trial name
- FREEDOM-1 (NCT03995901)
- Testing
- FCR001
- Where
- 18 sites in United States
- Volunteers
- 15 people
- Sponsor
- Talaris Therapeutics Inc.
Function of Renal Transplant
RituxiMab INDuction in Renal Transplantation
Hypothesis: That B cell depletion, rather than reducing acute rejection, will allow minimisation of immunosuppression, which may lead to better graft survival.
- Trial name
- ReMIND (NCT01095172)
- Testing
- Rituximab, Tacrolimus, Mycophenylate mofetil
- Where
- 6 sites in United Kingdom
- Volunteers
- 100 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Aspergillosis
Surveillance of Fungal Infections During Construction Activity
Fungal infections in immunocompromised patients occuring during construction activities in hospitals have repeatedly been reported.
- Trial name
- NCT00473252
- Where
- Switzerland
- Volunteers
- 340 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Kidney Transplantation, Chronic Kidney Failure
Early Conversion From Tacrolimus to Efalizumab Maintenance Therapy in Kidney Transplant Recipients
The toxicity of calcineurin inhibitors(CNI)is a major factor limiting the success of renal transplantation. This protocol aims to replace the calcineurin inhibitor, tacrolimus, with efalizumab early after transplantation in…
- Trial name
- NCT00472082
- Testing
- efalizumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Emory University
Kidney Failure, Renal Failure
Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients
The purpose of this study is to demonstrate the pharmacokinetics (PK, measuring the amount of medication in blood samples) and safety of a new medicine, LCP-Tacro™ tablets, and Prograf® capsules, a drug commonly taken by…
- Trial name
- NCT00765661
- Testing
- Tacrolimus (Tacro™), Prograf
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Veloxis Pharmaceuticals
Islet Cell Transplantation, Type 1 Diabetes
Pancreatic Islet Cell Transplantation After Kidney Transplantation - A Novel Approach to Immunosupression
The purpose of this study is to further test islet cell transplant in patients who have had a kidney transplant. This study will also evaluate the safety and effectiveness of the anti-rejection medications used to prevent…
- Trial name
- NCT03047200
- Testing
- Islet cell transplantation
- Where
- United States
- Sponsor
- Baylor Research Institute
Diabetes Mellitus, Type 1
Islet Transplantation for Patients With Type 1 Diabetes
This protocol will test whether Type 1 diabetes (T1DM) can be reversed in patients with stable renal allografts by islet transplantation.
- Trial name
- NCT00073281
- Testing
- Islet transplantation
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Kidney Transplant, Immunosuppression
Prospective Cohort of Kidney Transplanted Patients Receiving an Extended Releasing Tacrolimus-Everolimus Association
The tacrolimus-Everolimus association is used as an immunospressive treatment after a kidney transplant. It combined immunosupressive properties of both products and reduce the nephrotoxicity of tacrolimus by lowering the dosage.
- Trial name
- NCT03228576
- Testing
- Extended release Tacrolimus-Everolimus association
- Where
- 9 sites in France
- Volunteers
- 16 people
- Sponsor
- Poitiers University Hospital
Renal Transplantation
Combined Kidney and Hematopoietic Stem Cell Transplantation for Tolerance Induction
Combined transplantation of kidney and bone marrow between HLA-matched sibling donor-recipient pairs to induce immune tolerance in order to enable complete discontinuation of immunosuppressive therapy without kidney rejection.
- Trial name
- NCT05086003
- Testing
- Combined kidney and bone marrow transplantation
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Rabin Medical Center
Cytomegalovirus Infections
Valganciclovir Prophylaxis Versus Preemptive Therapy for Cytomegalovirus in Living Donor Kidney Transplant Recipients
Cytomegalovirus (CMV) infection remains one of the most frequent infectious complications after kidney transplantation. In intermediate-risk recipients (seropositive, R+ recipient) of living donor kidney transplants, optimal…
- Trial name
- (PREVAIL-KT) (NCT07430683)
- Testing
- Valganciclovir Prophylaxis, Preemptive Therapy (CMV PCR Monitoring)
- Where
- Mexico
- Volunteers
- 68 people
- Sponsor
- University of Guadalajara
Immunosuppression, Renal Failure
Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation.
This study will examine the renal sparing impact of implementing a strategy of conversion to everolimus from a calcineurin inhibitor based immunosuppressive protocol at 3 months post liver transplant
- Trial name
- NCT01936519
- Testing
- Arm A: Everolimus, Calcineurin Inhibitor
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Milton S. Hershey Medical Center
Pediatric Heart Transplantation, Immunosuppression
Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score
The TEAMMATE Trial will enroll 210 pediatric heart transplant patients from 25 centers at 6 months post-transplant and follow each patient for 2.5 years.
- Conditions
- Pediatric Heart Transplantation, Immunosuppression, Chronic Kidney Diseases, Cardiac Allograft Vasculopathy
- Trial name
- TEAMMATE (NCT03386539)
- Testing
- Everolimus, Tacrolimus, Mycophenolate Mofetil
- Where
- 25 sites in United States
- Volunteers
- 211 people
- Sponsor
- Boston Children's Hospital
Kidney Failure, Chronic, Transplantation
Fibrosis in Renal Allografts
This prospective, randomized study, comparing sirolimus to cyclosporine in renal transplant recipients, has two major objectives: 1.
- Conditions
- Kidney Failure, Chronic, Transplantation, Immunosuppression, Interstitial Fibrosis
- Trial name
- NCT00493194
- Testing
- sirolimus, cyclosporine, daclizumab
- Where
- 3 sites in Belgium
- Volunteers
- 100 people
- Sponsor
- University Hospital, Antwerp
Kidney Transplantation
REgulatory T Cell Therapy to Achieve Immunosuppression REduction
The goal of this multi-national, multi-center, open-label, randomized Phase 2 trial is to determine the safety and efficacy of administering expanded regulatory T cells (TRK-001) to prevent allograft rejection in living donor…
- Trial name
- RETIRE (NCT06552169)
- Testing
- Arm 1: SOC (mTOR + CNI), Arm 2A: TRACT/MONO mTOR, Arm 2B: TRACT/MONO CNI
- Where
- 7 sites in United States, Taiwan
- Volunteers
- 34 people
- Sponsor
- Singulera Therapeutics Inc.
Kidney Transplant Immunosuppression
The Role of ImmuKnow® in the Management of Immunosuppressants in the Renal Transplant Patient
The purpose of this study is to demonstrate whether there are any outcome benefits of a serial ImmuKnow assays in the management of de novo renal transplant recipients.
- Trial name
- NCT01424345
- Testing
- adjustment of immunosuppressant dosages, adjustment of the dosages of immunosuppressants
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- CAMC Health System
Covid19, Kidney Transplantation
Monitoring of COVID-19 Vaccine Response in Organ Transplant Patients
Vaccination against SARS CoV-2 appears to be the best strategy today to control the COVID-19 pandemic. The first published studies with Pfizer, Moderna and Astra-Zeneca vaccines show very good vaccine protection in the general…
- Trial name
- COVATRANS (NCT04828460)
- Where
- France
- Volunteers
- 3,500 people
- Sponsor
- University Hospital, Strasbourg, France
Diabetes, Immunosuppression
Evaluate Tolerability of Myfortic®/Simulect® and Tacrolimus Without Steroids in Three Patient Populations
This study is designed to evaluate the tolerability of Myfortic®/Simulect® combination in diabetic patients in a steroid free regimen.
- Trial name
- NCT01387659
- Testing
- Gastric emptying test
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- The University of Texas Medical Branch, Galveston
SARS-CoV-2 Infection, Active Immunization
Saxon SARS-CoV-2 Infection and Vaccination Study in Dialysis Patients, Solid Organ Recipients and Staff
To investigate short- (3 and 8 weeks) and long-term (6, 9, 12, and 18 months) immune protection or response at the humoral and cellular levels before and after SARS-CoV-2 infection or vaccination in patients with moderately…
- Conditions
- SARS-CoV-2 Infection, Active Immunization, Immune Response, Immunosuppression
- Trial name
- DIA-Vacc (NCT04799808)
- Where
- Germany
- Volunteers
- 3,500 people, healthy volunteers welcome
- Sponsor
- Technische Universität Dresden